{"paper_id":"caac3045-9aa1-4f9f-951b-419637a2a7c7","body_text":"Abstract\nThese are two of the most common gynecologic diseases, affecting 15% to 80% of women of childbearing age diseases. The existing treatments, such as hormonal drugs and selective estrogen receptor modulators like raloxifene, have side effects and recurrence, and thus indicate the need for less harmful non-hormonal therapies. Therefore, this study aimed at exploring plant-derived secondary metabolites as potential ESR1 inhibitors by focusing on the identification of natural ligands characterized by high binding affinity and structural stability and by providing preliminary insights into pharmacokinetic and safety aspects via in silico analysis. Forty structurally diverse phytochemicals were docked into the ESR1 ligand-binding pocket using AutoDock Vina and PyRx, with raloxifene as reference. Procyanidin, the top-scoring ligand, was selected for molecular dynamics (MD) simulations (100 ns, GROMACS) under physiological conditions. Structural stability was assessed by RMSD, RMSF, SASA, and radius of gyration (Rg), while ligand retention was evaluated using center-of-mass (COM) and minimum distance analyses. Three independent 10-ns replicates were also performed to ensure reproducibility of MD results. Procyanidin outperformed raloxifene (− 11.1 kcal/mol) and other options like hesperidin and sanguinarine with the strongest binding (− 12.1 kcal/mol). Docking revealed hydrophobic interactions with Leu387 and Ala350 and hydrogen bonding with Glu353 and Arg394. MD simulations confirmed stable ESR1–procyanidin complexes, with constant RMSD and Rg, stable SASA, and limited flexibility of key binding residues. COM and distance analyses established long-term retention of the ligand, supported by hydrophobic and π–stacking over stable hydrogen bond-dominant binding. Binding free energy analysis (MM-PBSA) further verified a spontaneous and favorable interaction (ΔG_total = − 22.66 kJ mol−1), mainly driven by van der Waals and hydrophobic forces. Procyanidin is a phytochemical lead that shows promise for controlling ESR1 signaling in fibroids and endometriosis as a non-hormonal candidate. Procyanidin emerged as a promising in-silico lead for ESR1 modulation, showing high binding affinity and dynamic stability; nevertheless, further pharmacokinetic, ADMET, and experimental validation are required to substantiate its therapeutic potential.\nGraphical abstract\nSimilar content being viewed by others\nData availability\nNo datasets were generated or analysed during the current study.\nAbbreviations\n- ADMET:\n-\nAbsorption, distribution, metabolism, excretion, and toxicity\n- BBB:\n-\nBlood–brain barrier\n- COM:\n-\nCenter of mass\n- EGCG:\n-\nEpigallocatechin gallate\n- ESR1:\n-\nEstrogen receptor 1\n- GnRH:\n-\nGonadotropin-releasing hormone\n- IL-6:\n-\nInterleukin 6\n- lncRNA:\n-\nLong non-coding RNA\n- MD:\n-\nMolecular dynamics simulation\n- miRNA:\n-\nmicroRNA\n- NSAIDs:\n-\nNonsteroidal anti-inflammatory drugs\n- PDB:\n-\nProtein Data Bank\n- PLIP:\n-\nProtein–ligand interaction profiler\n- RA600:\n-\nRaloxifene (reference compound)\n- Rg:\n-\nRadius of gyration\n- RMSD:\n-\nRoot mean square deviation\n- RMSF:\n-\nRoot mean square fluctuation\n- SASA:\n-\nSolvent accessible surface area\n- SDF:\n-\nStructure data file\n- SERM:\n-\nSelective estrogen receptor modulator\n- SwissADME:\n-\nSwiss ADME prediction tool\n- TGF-β:\n-\nTransforming growth factor beta\n- TIP3P:\n-\nTransferable intermolecular potential with 3 points\n- TNF-α:\n-\nTumor necrosis factor-alpha\n- VEGF:\n-\nVascular endothelial growth factor\nReferences\nAli MA (2020) Phytochemicals targeting Estrogen receptor alpha: a computational docking study. J Mol Model 26(3):54\nBorahay MA, Asoglu MR, Mas A, Adam S, Kilic GS, Al-Hendy A (2017) Estrogen receptors and signaling in fibroids: role in pathobiology and therapeutic implications. Reproductive Sci 24(9):1235–1244\nBussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126(1):64\nBörzsei D, Szabó R, Hoffmann A, Veszelka M, Pávó I, Turcsán Z et al (2020) Distinct approaches of raloxifene: its far-reaching beneficial effects implicating the HO-system. Biomolecules 10(3):375\nChalopin M, Tesse A, Martínez MC, Rognan D, Arnal JF, Andriantsitohaina R (2010) Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PLoS ONE 5(1):e8554\nDaina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):42717\nDallakyan S (2024) PyRx–virtual screening tool\nDarden T, York D, Pedersen L (1993) Particle mesh ewald: an N ⋅log(N) method for Ewald sums in large systems. J Chem Phys 98(12):10089–10092\nEl Sabeh M, Saha SK, Afrin S, Islam MS, Borahay MA (2021) Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities. Mol Cell Biochem 476(9):3513–3536\nFanning SW (2020) Estrogen receptor alpha ligand binding domain in complex with raloxifene. Worldwide Protein Data Bank\nGabriel M, Fey V, Heinosalo T, Adhikari P, Rytkönen K, Komulainen T et al (2020) A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions. Sci Data 7(1):284\nGholamian S, Baghaee P, Doroudian M (2025) Nanotechnology in gene editing: pioneering CRISPR-Cas delivery systems to tackle antibiotic resistance. Adv Ther 8(3):2400412\nGoddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE (2018) UCSF chimerax: meeting modern challenges in visualization and analysis. Protein Sci 27:14–25\nGopalakrishnan C, Kamaraj B, Purohit R (2014) Mutations in MicroRNA binding sites of CEP genes involved in cancer. Cell Biochem Biophys 70(3):1933–1942\nHasyim DM, Musfiroh I, Hendra R, Fakih TM, Ikram NKK, Muchtaridi M (2025) In silico approaches for the discovery of novel pyrazoline benzenesulfonamide derivatives as anti-breast cancer agents against Estrogen receptor alpha (ERα). Appl Sci 15(15):8444\nHess B, Bekker H, Berendsen HJ, Fraaije JG (1997) A linear constraint solver for molecular simulations. J Comput Chem 18:1463–1472\nJames JP, Kumar P, Kumar A, Bhat KI, Shastry CS (2020) Silico anticancer evaluation, molecular docking and pharmacophore modeling of flavonoids against various cancer targets. Lett Drug Des Discov 17(12):1485–1501\nJorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2):926–935\nKamaraj B, Rajendran V, Sethumadhavan R, Purohit R (2013) In-silico screening of cancer associated mutation on PLK1 protein and its structural consequences. J Mol Model 19(12):5587–5599\nKanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M (2016) KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44(D1):D457–D462\nKim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A et al (2016) PubChem substance and compound databases. Nucleic Acids Res 44(D1):D1202–D1213\nKobylka P, Kucinska M, Kujawski J, Lazewski D, Wierzchowski M, Murias M (2022) Resveratrol analogues as selective Estrogen signaling pathway modulators: structure–activity relationship. Molecules 27(20):6973\nKriegel M, Muller YA (2021) ER-PRS*(-) (L536S, L372R) in complex with raloxifene. Worldw Protein Data Bank\nKumar P, Bhardwaj VK, Purohit R (2023) Dispersion-corrected DFT calculations and umbrella sampling simulations to investigate stability of Chrysin-cyclodextrin inclusion complexes. Carbohydr Polym 319:121162\nKumar A, Rajendran V, Sethumadhavan R, Purohit R (2014) Relationship between a point mutation S97C in CK1δ protein and its affect on ATP-binding affinity. J Biomol Struct Dyn 32(3):394–405\nLaskowski RA, Swindells MB (2011) LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Inf Model 51(10):2778–2786\nLecomte S, Demay F, Ferrière F, Pakdel F (2017) Phytochemicals targeting Estrogen receptors: beneficial rather than adverse effects? Int J Mol Sci 18(7):1381\nLindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO et al (2010) Improved side‐chain torsion potentials for the amber ff99SB protein force field. Proteins Struct Funct Bioinform 78(8):1950–1958\nLiu H, He S, Xue T, Wen S, Zhu Y (2025) Isoquercitrin promotes angiogenesis through the genomic signaling pathway of the estrogen receptor-alpha. Phytother Res 39(10):4802–4820\nLiu YN, Hu XJ, Liu B, Shang YJ, Xu WT, Zhou HF (2021) Network pharmacology-based prediction of bioactive compounds and potential targets of wenjing decoction for treatment of endometriosis. Evid Based Complement Altern Med 2021:1–12\nLiu D, Mei W, Kang J, Liao T, Wei Y, Jie L et al (2024) Casticin ameliorates Osteoarthritic cartilage damage in rats through PI3K/AKT/HIF-1α signaling. Chem Biol Interact 391:110897\nMorris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791\nNanashima N, Horie K, Tomisawa T, Chiba M, Nakano M, Fujita T et al (2015) Phytoestrogenic activity of blackcurrant (Ribes nigrum) anthocyanins is mediated through Estrogen receptor alpha. Mol Nutr Food Res 59(12):2419–2431\nNicolosi RM, Bonincontro G, Imperia E, Badiali C, De Vita D, Sciubba F et al (2023) Protective effect of procyanidin-rich grape seed extract against gram-negative virulence factors. Antibiotics 12(11):1615\nNitschké M, Bell A, Karaman S, Amouzgar M, Rutkowski JM, Scherer PE et al (2017) Retrograde lymph flow leads to chylothorax in Transgenic mice with lymphatic malformations. Am J Pathol 187(9):1984–1997\nNordeen SK, Kumar V, Bona BJ, Batson JD, Backos DS, Wempe MF (2025) Endocrine-disrupting activities of flavones on steroid receptors: structural requirements and synthesis of novel flavone with improved estrogenic activity. Biomedicines 13(3):748\nO’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. J Cheminform 3(1):33\nParrinello M, Rahman A (1981) Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 52(12):7182–7190\nPettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC et al (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612\nPowers CN, Setzer WN (2015) A molecular docking study of phytochemical estrogen mimics from dietary herbal supplements. Silico Pharmacol 3(1):4\nPuranik NV, Srivastava P, Bhatt G, John Mary DJS, Limaye AM, Sivaraman J (2019) Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for Estrogen receptor (ERα) by various parameters and molecular modelling approach. Sci Rep 9(1):7450\nPurohit R, Sethumadhavan R (2009) Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease. Interdiscip Sci 1(4):320–328\nR Core Team. R: A language and environment for statistical computing for Statistical Computing. Vienna, Austria (2024). Available from: https://www.R-project.org\nSalentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res 43(W1):W443–W447\nSano A (2017) Safety assessment of 4-week oral intake of proanthocyanidin-rich grape seed extract in healthy subjects. Food Chem Toxicol 108:519–523\nShao ZH, Hoek TL, Vanden, Xie J, Wojcik K, Chan KC, Li CQ et al (2003) Grape seed proanthocyanidins induce pro-oxidant toxicity in cardiomyocytes. Cardiovasc Toxicol 3(4):331–340\nSinyani A, Idowu K, Shunmugam L, Kumalo HM, Khan R (2023) A molecular dynamics perspective into Estrogen receptor Inhibition by selective flavonoids as alternative therapeutic options. J Biomol Struct Dyn 41(9):4093–4105\nSurrey ES (2023) GnRH agonists in the treatment of symptomatic endometriosis: a review. F S Rep 4(2):40–45\nSzklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R et al (2023) The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acids Res 53(D1):D730–D737\nTrott O, Olson AJ (2010) AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461\nvan Hoesel MH, Chen YL, Zheng A, Wan Q, Mourad SM (2021) Selective oestrogen receptor modulators (SERMs) for endometriosis. Cochrane Database Syst Rev 2021:5\nVan Gunsteren WF, Berendsen HJC (1988) A Leap-frog algorithm for stochastic dynamics. Mol Simul 1(3):173–185\nVersion 4 (2024) 4.1. Vienna ARF for SC. R Core Team. R: a language and environment for statistical computing. Available from: https://wwwR-project.org\nWang T, Liu Y, Zhuang X, Luan F, Zhao C (2021) The interaction of isoflavone phytoestrogens with ERα and ERβ by molecular docking and molecular dynamics simulations. Curr Comput Aided Drug Des 17(5):655–665\nWang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157–1174\nZineb OY, Rashwan AK, Karim N, Lu Y, Tangpong J, Chen W (2023) Recent developments in procyanidins on metabolic diseases, their possible sources, pharmacokinetic profile, and clinical outcomes. Food Rev Int 39(8):5255–5278\nFunding\nThis study was supported by Bam University of Medical Sciences, Bam, Iran (Grant# 404000018).\nAuthor information\nAuthors and Affiliations\nContributions\nAll authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Zahra Maravandi, Sahar Gholamian, and Ali Samadi. Molecular docking simulations were primarily conducted by Zahra Maravandi. Molecular dynamics simulations and interaction profiling were primarily conducted by Sahar Gholamian, who also handled graphic design for figures and visualizations. Transcriptomic analysis and ADMET profiling were overseen by Ali Samadi, who served as the corresponding author and handled funding acquisition and project management. The first draft of the manuscript was written by Zahra Maravandi. Ali Samadi, and Jeffrey D. Gross provided critical revisions, clinical insights, and edits for the final version. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\nCorresponding author\nEthics declarations\nCompeting interests\nThe authors declare no competing interests.\nEthical approval\nThe Ethics Committee of Bam University of Medical Sciences approved this study (Ethical code # IR.MUBAM.REC.1404.043). The research also followed the tenets of the Declaration of Helsinki. This study was extracted from a research project was conducted in Bam University of Medical Sciences. Additionally, ethical issues (including plagiarism, data fabrication and double publication) have been completely observed by the authors.\nAdditional information\nPublisher’s note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nMaravandi, Z., Gholamian, S., Samadi, A. et al. In silico evaluation of procyanidin as a potential ESR1 inhibitor: docking and MD insights in uterine fibroids and endometriosis. In Silico Pharmacol. 14, 29 (2026). https://doi.org/10.1007/s40203-025-00541-z\nReceived:\nAccepted:\nPublished:\nVersion of record:\nDOI: https://doi.org/10.1007/s40203-025-00541-z","source_license":"CC0","license_restricted":false}